Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Agus

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Gigascience|April 19, 2021
High-throughput microscopy reveals the impact of multifactorial environmental perturbations on colorectal cancer cell growthChun-Te Chiang, Roy Lau, Ahmadreza Ghaffarizadeh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenograftsDavid B Solit, Fuzhong F Zheng, Maria Drobnjak, et al.
BJU International|March 16, 2006
Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trialRonald L Shazer, Anjali Jain, Anna V Galkin, et al.
Investigational New Drugs|January 6, 2015
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancerDaniel P Petrylak, Jitendra G Gandhi, William R Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancerRobert Dreicer, David MacLean, Ajit Suri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus, Michael S Gordon, Charles Taylor, et al.
Cancer Cell|September 3, 2002
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthDavid B Agus, Robert W Akita, William D Fox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus, Christopher J Sweeney, Michael J Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2021
Paradoxical androgen receptor regulation by small molecule enantiomersKatherin Patsch, Chao Liu, Grzegorz Zapotoczny, et al.
Molecular Cancer Therapeutics|June 2, 2017
JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell LinesKian Kani, Carolina Garri, Katrin Tiemann, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Gigascience|April 19, 2021
High-throughput microscopy reveals the impact of multifactorial environmental perturbations on colorectal cancer cell growthChun-Te Chiang, Roy Lau, Ahmadreza Ghaffarizadeh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenograftsDavid B Solit, Fuzhong F Zheng, Maria Drobnjak, et al.
BJU International|March 16, 2006
Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trialRonald L Shazer, Anjali Jain, Anna V Galkin, et al.
Investigational New Drugs|January 6, 2015
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancerDaniel P Petrylak, Jitendra G Gandhi, William R Clark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancerRobert Dreicer, David MacLean, Ajit Suri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus, Michael S Gordon, Charles Taylor, et al.
Cancer Cell|September 3, 2002
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthDavid B Agus, Robert W Akita, William D Fox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus, Christopher J Sweeney, Michael J Morris, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2021
Paradoxical androgen receptor regulation by small molecule enantiomersKatherin Patsch, Chao Liu, Grzegorz Zapotoczny, et al.
Molecular Cancer Therapeutics|June 2, 2017
JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell LinesKian Kani, Carolina Garri, Katrin Tiemann, et al.
Pageof 8